ATR and neoplasm: Overall, the results generated here led to the development and optimization of a modified G2-assay using the VE-821 ATR inhibitor enabling time-efficient radiosensitivity assessments of cultured cells, and, potentially, of primary tumor cells obtained from biopsies.